MYC Articles


  • Generation of a C57BL/6 MYC-driven mouse model and cell line of prostate cancer.

    Transgenic mouse modeling is a favorable tool to reflect human prostate tumorigenesis and interactions between prostate cancer and the microenvironment. The use of GEMMs and derived cell lines represent powerful tools to study prostate cancer initiation and progression with an associated tumor microenvironment.

    Published June 3, 2016
  • Metabolic vulnerabilities of MYC-induced cancer.

    Renal cell carcinoma is often an untreatable disease suggesting that novel therapeutic approaches are required. We have found that, surprisingly, MYC-associated renal cell carcinoma may exhibit dependence upon specific metabolic programs with a unique vulnerability to glutamine inhibition.

    Published February 19, 2016
  • Novel drugs that target the metabolic reprogramming in renal cell cancer.

    Molecular profiling studies of tumor tissue from patients with clear cell renal cell cancer (ccRCC) have revealed extensive metabolic reprogramming in this disease. Associations were found between metabolic reprogramming, histopathologic Fuhrman grade, and overall survival of patients.

    Published July 18, 2016
  • The association between rs9642880 gene polymorphism and bladder cancer risk: a meta-analysis.

    Previous studies had researched the relationship between rs9642880 gene polymorphism and bladder cancer risk, but the results remained unclear. The comprehensive meta-analysis was performed to clarify this possible association.

    Published February 29, 2016
  • Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.

    The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate cancer (PC). MYC protein abundance is also increased in the majority of cases of advanced and metastatic castrate-resistant PC (mCRPC).

    Published February 21, 2017